2024. Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II. SKIN The Journal of Cutaneous Medicine. 8, 2 (Mar. 2024), s396. DOI:https://doi.org/10.25251/skin.8.supp.396.